The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Stephen Jordan, CEO of American Cannabis Partners, a multi-state cannabis company.

Throughout the interview, Jordan discussed the company’s business model and strategic approach to minimizing shareholder risk.

“American Cannabis Partners (“ACP”) is a multi-state operator. We have farms in Northern California, as well as the State of Michigan,” Jordan said. “We have 11 cultivation licenses totaling about 560,000 square foot of canopy space. These are acquired licenses, so it is fully legit. We have a retail license in the State of Michigan, as well. One of the biggest things for us… is assets and safety. That’s one of the hardest things to find in this industry. A lot of people and a lot of companies have products, but they’ve placed themselves in very strenuous liability situations. If they can’t make a product, they no longer have a company. ACP took the opposite direction.”

“We raised capital initially, step-by-step, and we deployed that money into tangible assets – real estate, equipment, things of that nature – just in case some type of bad situation came up or some type of change in a regulatory agency that was no longer a good fit for ACP in that location. We have the ability to liquidate, move and still stay afloat and protect our shareholders,” he continued. “That’s always been a big part for us – assets, assets, assets – and then build the operations out. To this day… we are cash-flow positive, shareholder distribution positive, and we are moving to our third state sometime in the latter half of 2022… preferably on the east coast.”

Jordan then provided some insight into his background in the cannabis sector.

Bell2Bell’s latest podcast features Stephen Jordan, CEO of American Cannabis Partners, a multi-state cannabis company.

Throughout the interview, Jordan discussed the company’s business model and strategic approach to minimizing shareholder risk.

“American Cannabis Partners (“ACP”) is a multi-state operator. We have farms in Northern California, as well as the State of Michigan,” Jordan said. “We have 11 cultivation licenses totaling about 560,000 square foot of canopy space. These are acquired licenses, so it is fully legit. We have a retail license in the State of Michigan, as well. One of the biggest things for us… is assets and safety. That’s one of the hardest things to find in this industry. A lot of people and a lot of companies have products, but they’ve placed themselves in very strenuous liability situations. If they can’t make a product, they no longer have a company. ACP took the opposite direction.”

“We raised capital initially, step-by-step, and we deployed that money into tangible assets – real estate, equipment, things of that nature – just in case some type of bad situation came up or some type of change in a regulatory agency that was no longer a good fit for ACP in that location. We have the ability to liquidate, move and still stay afloat and protect our shareholders,” he continued. “That’s always been a big part for us – assets, assets, assets – and then build the operations out. To this day… we are cash-flow positive, shareholder distribution positive, and we are moving to our third state sometime in the latter half of 2022… preferably on the east coast.”

Jordan then provided some insight into his background in the cannabis sector.

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

“This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”

Bell2Bell’s latest podcast features Gregory Wagner, CEO of RYAH Group Inc. During the briefing, Wagner discussed the company’s goals and milestones in 2021, as well as providing an overview of RYAH’s business model and product offerings.

“The main item that we’re discussing is obviously our listing on the Canadian Securities Exchange (CSE), with our ticker being ‘RYAH’,” Wagner said. “It was quite a long journey through a reverse takeover (RTO) transaction. We are very pleased to have some of our shareholder have access to the electronic markets after being with us for so many years, and we’re excited for achieving the next chapter of the company’s history.”